Celldex Therapeutics, Inc. (CLDX) stock
CLDXNasdaqIn Vitro & In Vivo Diagnostic SubstancesFiscal year ends December 31
$28.83+0.30 (+1.05%)
Close on Nov 13, 2026Market cap $2.26BP/E –Yield –
Celldex Therapeutics operating margin
Operating margin is operating income as a percentage of revenue.
Celldex Therapeutics's operating margin for the twelve months ending Sep 30, 2026 was -211684.8%. For fiscal 2025 it was -18599.8%, against -2778.9% the year before. The highest annual figure on record is -13.8% in fiscal 2010.
Annual operating margin
| Period | Period end | Value | Change (pts) |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | -18599.8% | −15820.9 |
| FY2024 | Dec 31, 2024 | -2778.9% | −533.6 |
| FY2023 | Dec 31, 2023 | -2245.3% | +2643.7 |
| FY2022 | Dec 31, 2022 | -4889.0% | −3357.2 |
| FY2021 | Dec 31, 2021 | -1531.8% | −677.7 |
| FY2020 | Dec 31, 2020 | -854.1% | +686.1 |
| FY2019 | Dec 31, 2019 | -1540.2% | +99.9 |
| FY2018 | Dec 31, 2018 | -1640.1% | −686.5 |
| FY2017 | Dec 31, 2017 | -953.7% | +1005.0 |
| FY2016 | Dec 31, 2016 | -1958.7% | +405.2 |
| FY2015 | Dec 31, 2015 | -2363.9% | +1050.2 |
| FY2014 | Dec 31, 2014 | -3414.1% | −1433.0 |
| FY2013 | Dec 31, 2013 | -1981.1% | −1462.6 |
| FY2012 | Dec 31, 2012 | -518.5% | −50.0 |
| FY2011 | Dec 31, 2011 | -468.4% | −454.6 |
| FY2010 | Dec 31, 2010 | -13.8% | +229.0 |
| FY2009 | Dec 31, 2009 | -242.8% | – |
Quarterly operating margin
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change (pts) |
|---|---|---|---|
| Q2 FY2026 | Jun 30, 2026 | -366468.2% | −357441.0 |
| Q1 FY2026 | Mar 31, 2026 | -562900.0% | −558131.7 |
| Q4 FY2025 | Dec 31, 2025 | -72027.3% | −70393.7 |
| Q2 FY2025 | Jun 30, 2025 | -8747.5% | −6893.4 |
| Q1 FY2025 | Mar 31, 2025 | -9027.2% | +17003.6 |
| Q4 FY2024 | Dec 31, 2024 | -4768.3% | −3615.3 |
| Q3 FY2024 | Sep 30, 2024 | -1633.5% | +1084.9 |
| Q2 FY2024 | Jun 30, 2024 | -1854.2% | +10535.8 |
| Q1 FY2024 | Mar 31, 2024 | -26030.8% | −22672.9 |
| Q4 FY2023 | Dec 31, 2023 | -1152.9% | +575.8 |
| Q3 FY2023 | Sep 30, 2023 | -2718.5% | +4086.5 |
| Q2 FY2023 | Jun 30, 2023 | -12389.9% | +9938.9 |
| Q1 FY2023 | Mar 31, 2023 | -3357.9% | +10008.2 |
| Q4 FY2022 | Dec 31, 2022 | -1728.8% | +4361.1 |
| Q3 FY2022 | Sep 30, 2022 | -6804.9% | +6805.5 |
| Q2 FY2022 | Jun 30, 2022 | -22328.8% | −21942.6 |
| Q1 FY2022 | Mar 31, 2022 | -13366.1% | −10937.0 |
| Q4 FY2021 | Dec 31, 2021 | -6089.8% | −5435.3 |
| Q3 FY2021 | Sep 30, 2021 | -13610.5% | −11463.5 |
| Q2 FY2021 | Jun 30, 2021 | -386.2% | +4429.5 |
| Q1 FY2021 | Mar 31, 2021 | -2429.1% | −1957.4 |
| Q4 FY2020 | Dec 31, 2020 | -654.5% | +809.8 |
| Q3 FY2020 | Sep 30, 2020 | -2147.0% | +22.2 |
| Q2 FY2020 | Jun 30, 2020 | -4815.7% | −3101.4 |
| Q1 FY2020 | Mar 31, 2020 | -471.7% | +787.4 |
| Q4 FY2019 | Dec 31, 2019 | -1464.4% | −777.1 |
| Q3 FY2019 | Sep 30, 2019 | -2169.2% | −1344.2 |
| Q2 FY2019 | Jun 30, 2019 | -1714.3% | −1103.6 |
| Q1 FY2019 | Mar 31, 2019 | -1259.0% | +1682.9 |
| Q4 FY2018 | Dec 31, 2018 | -687.2% | +51.4 |
| Q3 FY2018 | Sep 30, 2018 | -825.1% | −10.6 |
| Q2 FY2018 | Jun 30, 2018 | -610.7% | +144.8 |
| Q1 FY2018 | Mar 31, 2018 | -2941.9% | −653.0 |
| Q4 FY2017 | Dec 31, 2017 | -738.6% | +1121.2 |
| Q3 FY2017 | Sep 30, 2017 | -814.5% | – |
| Q2 FY2017 | Jun 30, 2017 | -755.5% | – |
| Q1 FY2017 | Mar 31, 2017 | -2288.9% | – |
| Q4 FY2016 | Dec 31, 2016 | -1859.8% | – |
See a number that looks wrong?